Previous 10 | Next 10 |
2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...
Shortly after today’s market open, the NASDAQ Biotechnology Index crossed the 5,000-point mark for the first time, continuing the four-day winning streak.However, the index has lost some early gains with a subsequent dip causing it to hover slightly below the historical milestone.With ...
Healthcare stocks are soaring as clarity emerges over the outcome of the Georgia Senate runoff elections. Earlier in the day, Associated Press reported Democrat Raphael Warnock defeated Republican incumbent Sen. Kelly Loeffler tipping the scale towards Democrats to claim a narrow lead in...
The iShares Nasdaq Biotechnology ETF includes both COVID-19 and other plays. The ETF is up by 26% during the last year and there are questions around further growth. While some analysts have a neutral stance, there are some indications which point to more upside, despite uncertain...
Heading into 2021, Baird keeps a neutral view on Biotechnology despite higher expectations after the sector with a 26% gain in the iShares Nasdaq Biotechnology ETF (IBB) outperformed in 2020 compared to the 16% in the SPDR S&P 500 Trust ETF (SPY). The outlook is underpinned by uncertainty...
2020 was the year the biotech sector roared back to life. Led by COVID-19 vaccine developers, the iShares Nasdaq Biotechnology ETF (IBB) returned 25.7% compared to 16.2% in the SPDR S&P 500 Trust ETF (SPY), signaling a remarkable turnaround from 2019 when SPY, with a 28.8% gain, outp...
As the year closes out, Abiomed (ABMD) is leading the S&P 500 constituents to become the highest gainer for 2020. With the 2.6% added today, the total return for the year is reaching 83.4% YTD, well outperforming the 17.8% gain in the SPDR S&P 500 Trust ETF (SPY). ...
As the IPO quiet period ends, Kinnate Biopharma (KNTE) is enticing bullish views on Wall Street. The analysts from SVB Leerink, Piper Sandler, Wedbush, and Goldman Sachs have all weighed in with buy ratings for Kinnate. The target price ranges from $48 - $60, an upside of 26.3% - 57...
OPK touts a $900 million potential for its Rayaldee drug that is unlikely to be achieved. The recent increase in revenue is almost entirely attributed to COVID-19 testing. Once a vaccine rollout is complete, revenue should revert to normal levels, and share price will follow. OPK ...
Despite warnings from health officials to limit travel amid rising COVID-19 cases in the U.S., more than 6.7M people have passed through TSA checkpoints in the seven days heading into Christmas, That is over a 3% increase for the same period through Thanksgiving Day last month....
News, Short Squeeze, Breakout and More Instantly...
iShares Biotechnology ETF Company Name:
IBB Stock Symbol:
NASDAQ Market:
2024-07-19 00:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 22:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...